Demographic and clinical characteristics of oncology patients and controls
| . | All (N = 43) . | Patients with malignancies (n = 20) . | Controls (n = 23) . |
|---|---|---|---|
| Age, y | 52 (34-56) | 56 (40-60) | 49 (34-54) |
| Male sex | 20 (47) | 15 (75) | 5 (22) |
| Non-White race | 15 (35) | 3 (15) | 12 (52) |
| BMI, kg/m2 | 32.0 (29.6-41.4) | 29 (27.0-31.6) | 39.7 (32.0-47.0) |
| BSA, m2 | 2.1 (2.0-2.3) | 2.1 (1.9-2.3) | 2.2 (2.0-2.5) |
| Waist/ hip ratio | 0.91 (0.84-0.97) | 0.92 (0.90-0.99) | 0.89 (0.84-0.95) |
| Family history of diabetes | 14 (32) | 5 (25) | 9 (39) |
| History of hypertension | 18 (42) | 12 (60) | 6 (26) |
| Use of hypertension medication | 15 (35) | 12 (60) | 3 (13) |
| Systolic blood pressure, mmHg | 122 (112-133) | 122 (111-136) | 122 (116-133) |
| Diastolic blood pressure, mmHg | 76 (70-81) | 73 (68-80) | 77 (72-84) |
| Type of malignancy | |||
| AML | — | 5 (25) | — |
| ALL | — | 1 (5) | — |
| CML | — | 1 (5) | — |
| MDS | — | 3 (15) | — |
| MPN | — | 3 (15) | — |
| NHL | — | 7 (35) | — |
| Any DTA mutation | — | 5 (25) | — |
| Disease duration, mo | — | 9.5 (6-39.5) | — |
| Systemic chemotherapy | — | 17 (85) | — |
| Anthracyclines | — | 12 (60) | — |
| Alkylating agents | — | 7 (35) | — |
| Corticosteroid treatment | — | 8 (40) | — |
| Radiotherapy | — | 4 (20) | — |
| Complete response to treatment | — | 11 (55) | — |
| . | All (N = 43) . | Patients with malignancies (n = 20) . | Controls (n = 23) . |
|---|---|---|---|
| Age, y | 52 (34-56) | 56 (40-60) | 49 (34-54) |
| Male sex | 20 (47) | 15 (75) | 5 (22) |
| Non-White race | 15 (35) | 3 (15) | 12 (52) |
| BMI, kg/m2 | 32.0 (29.6-41.4) | 29 (27.0-31.6) | 39.7 (32.0-47.0) |
| BSA, m2 | 2.1 (2.0-2.3) | 2.1 (1.9-2.3) | 2.2 (2.0-2.5) |
| Waist/ hip ratio | 0.91 (0.84-0.97) | 0.92 (0.90-0.99) | 0.89 (0.84-0.95) |
| Family history of diabetes | 14 (32) | 5 (25) | 9 (39) |
| History of hypertension | 18 (42) | 12 (60) | 6 (26) |
| Use of hypertension medication | 15 (35) | 12 (60) | 3 (13) |
| Systolic blood pressure, mmHg | 122 (112-133) | 122 (111-136) | 122 (116-133) |
| Diastolic blood pressure, mmHg | 76 (70-81) | 73 (68-80) | 77 (72-84) |
| Type of malignancy | |||
| AML | — | 5 (25) | — |
| ALL | — | 1 (5) | — |
| CML | — | 1 (5) | — |
| MDS | — | 3 (15) | — |
| MPN | — | 3 (15) | — |
| NHL | — | 7 (35) | — |
| Any DTA mutation | — | 5 (25) | — |
| Disease duration, mo | — | 9.5 (6-39.5) | — |
| Systemic chemotherapy | — | 17 (85) | — |
| Anthracyclines | — | 12 (60) | — |
| Alkylating agents | — | 7 (35) | — |
| Corticosteroid treatment | — | 8 (40) | — |
| Radiotherapy | — | 4 (20) | — |
| Complete response to treatment | — | 11 (55) | — |
Data are presented as median (IQR) for continuous variables and n (%) as categorical variables.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BSA, body surface area; CML, chronic myelogenous leukemia; DTA, DNMT3A, TET2, or ASXL1; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.